Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM04755 MAD study in healthy subjects
NCT03229291Phase 1Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SM04755 in tendinopathy (4 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Incidence of adverse events at Day 28, Incidence of clinical laboratory abnormalities at Day 28 and 13 more. Started Nov 2016; status: completed.
02
Drugs
SM04755
03
Conditions
tendinopathy
Beyond the preview
Go deeper on NCT03229291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229291.